Ozono Seiichiro, Furuse Hiroshi
Nihon Rinsho. 2014 Dec;72(12):2170-3.
Cabazitaxel, new chemotherapeutic agent for castration resistant prostate cancer (CRPC) treated after docetaxel, was developed. In addition, new hormonal drugs for CRPC, such as enzalutamide and abiraterone were also approved in Japan recently. Treatment strategy for CRPC using these drugs is still controversial, therefore we need much more clinical data of Japanese patients with CRPC. Management of this severe condition and future of prostate cancer were discussed.
卡巴他赛，一种用于多西他赛治疗后去势抵抗性前列腺癌（CRPC）的新型化疗药物被研发出来。此外，用于CRPC的新型激素药物，如恩杂鲁胺和阿比特龙，最近在日本也获得了批准。使用这些药物治疗CRPC的策略仍存在争议，因此我们需要更多日本CRPC患者的临床数据。讨论了这种严重疾病的管理以及前列腺癌的未来。
